Sign in

CIK 0001668243

  • Non-accelerated filer
  • Smaller reporting company

UroGen Pharma Ltd.

Sign in to watch
Ticker
URGN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
Israel
Entity type
Operating
Phone
+972 97707601
Business address
9 HA'TA'ASIYA ST, RA'ANANA, Israel, 4365007
  1. 4 Open-market sale Chief Medical Officer sold 5,149 shares at $19.14 ($98,552)
  2. 4 Open-market sale Chief Medical Officer sold 5,162 shares at $7.37 ($38,044)
  3. 4 Open-market sale Chief Medical Officer sold 4,551 shares at $11.14 ($50,698)
  4. 4 Open-market sale General Counsel sold 7,379 shares at $11.14 ($82,202)
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 3 Insider Initial Statement of Ownership
  8. 4 Open-market sale Chief Medical Officer sold 859 shares at $13.08 ($11,236)
  9. 4 Open-market sale General Counsel sold 1,521 shares at $13.08 ($19,895)
  10. 4 Exercise or conversion Chief Financial Officer acquired 2,500 shares (option exercise)
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Derivatives Options or other derivatives
  16. 4 Derivatives Options or other derivatives
  17. 4 Derivatives Options or other derivatives
  18. 4 Open-market sale Chief Medical Officer sold 5,153 shares at $13.08 ($67,401)
  19. 4 Open-market sale Chief Medical Officer sold 12,000 shares at $14.05 ($168,600)
  20. 4/A Exercise or conversion Chief Financial Officer acquired 3,333 shares (option exercise)

Page 3 of 12 · 233 filings